Nanobiotix appoints ex-Sanofi head Alain Herrera
pharmafile | February 14, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | Sanofi, nanobiotix
Nanomedicine firm Nanobiotix has announced that Dr Alain Herrera joins its Supervisory Board, succeeding Thierry Chopin and Isabelle Bou Antoun in their roles.
Herrera joins the Board with more than 25 years of experience in the pharma industry, focussed in the areas of oncology drug development and marketing.
Before setting up his own oncology consultancy – Alain Oncologie Consulting (AOC) – he headed the oncology business at Sanofi-Aventis for 10 years, where he was VP for the Global Oncology Business Strategy and Development (2007-2008) and head of the Global Oncology Franchise (1998-2007).
His previous responsibilities within the pharma industry included the roles of chairman of Chiron Therapeutics Europe, managing director at Pierre Fabre Oncology Laboratories and head of the Oncology Platform at Roger Bellon (Rhône Poulenc). In addition to these roles, since 1991, Herrera has been a hematologist consultant at Antoine Beclere Hospital.
Herrera said: “I’m both delighted and privileged to be able to play a part in helping Nanobiotix to deliver its objectives and to overcome the challenges that lie ahead. I look forward to working with the Nanobiotix team.”
“We welcome Dr Alain Herrera to the Supervisory Board. Pioneer of industrial oncology, his business and pharmaceutical industry experience will add important expertise to the Board,” said Laurent Levy, chief executive of Nanobiotix.
Related Content
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …
